Crossmark

Development of a multicomponent implementation strategy to reduce upper gastrointestinal bleeding risk in patients using warfarin and antiplatelet therapy, and protocol for a pragmatic multilevel randomized factorial pilot implementation trial

Crossref DOI link: https://doi.org/10.1186/s43058-022-00256-8

Published Online: 2022-01-28

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kurlander, Jacob E. https://orcid.org/0000-0003-1798-060X
Helminski, Danielle

Lanham, Michael

Henstock, Jennifer L.

Kidwell, Kelley M.

Krein, Sarah L.

Saini, Sameer D.

Richardson, Caroline R.

De Vries, Raymond

Resnicow, Kenneth

Ruff, Allison Laboon

Wallace, David M.

Jones, Elizabeth K.

Perry, Linda K.

Parsons, Jacqueline

Ha, Nghi

Alexandris-Souphis, Tina

Dedrick, Dale

Aldridge, Elizabeth

Barnes, Geoffrey D.
Funding

Funding for this research was provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (K23DK 118179)

U.S. Department of Veterans Affairs (RCS 11-222)
License Information

Text and Data Mining valid from 2022-01-28

Version of Record valid from 2022-01-28
More Information

Article History

Received: 22 November 2021

Accepted: 9 January 2022

First Online: 28 January 2022

Declarations

:

: This study was approved by the University of Michigan institutional review board (HUM00201535) on September 10, 2021.

: Not applicable.

: GDB receives consulting fees from Pfizer/Bristol-Myers Squibb, Jansen, and Acelis Connected Health. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below